74 research outputs found
Modulateurs du transport vésiculaire du glutamate (développement d'outils pharmacologiques et de diagnostic pour la maladie d'Alzheimer)
Résumé en français confidentielRésumé en anglais confidentielPARIS5-Bibliotheque electronique (751069902) / SudocPARIS-BIUM-Bib. électronique (751069903) / SudocSudocFranceF
Nouvelles approches en cancérologie "les cicbles Met et p53" (SynthÚse, optimisation et études du mécanisme d'action de nouveaux dérivés aminothiazoles)
AIX-MARSEILLE2-BU Sci.Luminy (130552106) / SudocSudocFranceF
Stimuler la rĂ©ponse interfĂ©ron de type I avec des petites molĂ©cules : le renouveau dâune vieille idĂ©e
Les interfĂ©rons de type I jouent un rĂŽle central dans la mise en place dâune rĂ©ponse immunitaire innĂ©e contre les infections virales et les cellules tumorales. Peu aprĂšs leur dĂ©couverte en 1957, plusieurs Ă©quipes ont recherchĂ© des petites molĂ©cules capables dâinduire lâexpression de ces cytokines Ă des fins thĂ©rapeutiques. Un ensemble de composĂ©s actifs chez la souris ont ainsi Ă©tĂ© identifiĂ©s, mais en raison de leur relative inefficacitĂ© chez lâhomme pour des raisons incomprises Ă lâĂ©poque, ces travaux ont Ă©tĂ© abandonnĂ©s et sont tombĂ©s dans lâoubli. Ces derniĂšres annĂ©es, la caractĂ©risation des rĂ©cepteurs impliquĂ©s dans la reconnaissance des pathogĂšnes, des voies de signalisation quâils activent, ainsi que la dĂ©couverte des cellules dendritiques plasmacytoĂŻdes ont rĂ©volutionnĂ© notre comprĂ©hension de lâimmunitĂ© innĂ©e. Ces dĂ©couvertes et les nouvelles technologies de criblages Ă haut dĂ©bit ont ravivĂ© lâintĂ©rĂȘt pour les petites molĂ©cules capables dâinduire les interfĂ©rons de type I. Les preuves de leur efficacitĂ© thĂ©rapeutique chez lâhomme sont attendues trĂšs prochainement
Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions
International audienceVesicular glutamate transporters (VGLUTs) were long thought to be specific markers of glutamatergic excitatory transmission. The discovery, two decades ago, of the atypical VGLUT3 has thoroughly modified this oversimplified view. VGLUT3 is strategically expressed in discrete populations of glutamatergic, cholinergic, serotonergic, and even GABAergic neurons. Recent reports show the subtle, but critical, implications of VGLUT3-dependent glutamate co transmission and its roles in the regulation of diverse brain functions and dysfunctions. Progress in the neuropharmacology of VGLUT3 could lead to decisive breakthroughs in the treatment of Parkinson's disease (PD), addiction, eating disorders, anxiety, presbycusis, or pain. This review summarizes recent findings on VGLUT3 and its vesicular underpinnings as well as on possible ways to target this atypical transporter for future therapeutic strategies
SELECTIVE ORGANIC CATION TRANSPORTERS INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS
The invention relates to organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. The invention is also directed to pharmaceutical compositions comprising such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders
Molecular, Structural, Functional, and Pharmacological Sites for Vesicular Glutamate Transporter Regulation
International audienceVesicular glutamate transporters (VGLUTs) control quantal size of glutamatergic transmission and have been the center of numerous studies over the past two decades. VGLUTs contain two independent transport modes that facilitate glutamate packaging into synaptic vesicles and phosphate (Pi) ion transport into the synaptic terminal. While a transmembrane proton electrical gradient established by a vacuolar-type ATPase powers vesicular glutamate transport, recent studies indicate that binding sites and flux properties for chloride, potassium, and protons within VGLUTs themselves regulate VGLUT activity as well. These intrinsic ionic binding and flux properties of VGLUTs can therefore be modulated by neurophysiological conditions to affect levels of glutamate available for release from synapses. Despite their extraordinary importance, specific and high-affinity pharmacological compounds that interact with these sites and regulate VGLUT function, distinguish between the various modes of transport, and the different isoforms themselves, are lacking. In this review, we provide an overview of the physiologic sites for VGLUT regulation that could modulate glutamate release in an over-active synapse or in a disease state
Regulation of IRE1 RNase activity by the Ribonuclease inhibitor 1 (RNH1)
International audienc
Purification and characterization of recombinant human liver glycolate oxidase
International audienc
- âŠ